Elicio Therapeutics, Inc. quarterly report, Q1 FY2021

Filing identity and reporting period

Important mismatch: The request identifies Elicio Therapeutics, Inc., but the supplied Form 10-Q is for Angion Biomedica Corp. (Nasdaq: ANGN). This summary covers Angion’s unaudited quarter ended March 31, 2021; it should not be treated as an Elicio filing summary.

Angion is a clinical-stage biopharmaceutical company developing ANG-3777 for acute organ injuries and other candidates for fibrotic diseases. It had no approved products and no product-sales revenue.

Financial performance and position

Revenue was contract revenue recognized over time from the Vifor Pharma license; there was no grant revenue in Q1 2021, compared with $0.865 million in Q1 2020. Operating expenses rose as staffing and clinical/preclinical activity expanded. Other expense increased substantially, including $14.6 million of fair-value changes in warrants, convertible notes and preferred stock, and higher interest expense. The filing reports no meaningful operating margin given the small revenue base and operating loss.

At March 31, 2021, cash and cash equivalents were $130.456 million, current assets $133.498 million, current liabilities $16.963 million, and working capital $116.535 million. Total assets were $139.200 million and total liabilities $46.757 million. Accumulated deficit was $197.249 million. Convertible notes and Series C preferred stock had converted to common stock following the February IPO; $0.714 million of warrant liability remained. The balance sheet also included $0.895 million of other short-term debt and $4.930 million of operating lease liabilities.

Financing cash flow was $108.444 million, primarily from approximately $110.6 million of net IPO and concurrent private-placement proceeds. Cash increased $95.849 million during the quarter. Management said existing cash was expected to fund planned operations for at least 12 months from issuance of the financial statements; the company nevertheless expected substantial ongoing losses and future financing needs.

Material changes, outlook and risks

• Angion completed its IPO on February 9, 2021, issuing 5.75 million shares at $16 per share, and completed a concurrent Vifor-affiliated private placement of 1.5625 million shares. Outstanding convertible notes and preferred stock converted into common shares.
• Management expected R&D and G&A spending to increase as programs advanced. No product-sales revenue was expected for several years, if ever; future revenue depended in part on collaboration payments and eventual product development and commercialization.
• Enrollment was complete in the Phase 2 ANG-3777 trial for cardiac-surgery-associated acute kidney injury and in a Brazil Phase 2 trial for COVID-19-associated acute lung injury. A subsequent event reported completion of enrollment in the cardiac-surgery trial on April 29, 2021.
• A key regulatory uncertainty concerns the ANG-3777 Phase 3 delayed-graft-function trial: the company changed its primary endpoint to eGFR measured over 12 months after transplant, but the FDA had not agreed with the endpoint change and cited unresolved questions about whether eGFR adequately predicts clinical benefit. FDA acceptance and the trial’s ability to support approval were uncertain.
• COVID-19 restrictions had affected enrollment and trial operations. The company reported no expected 2021 investigational-drug supply disruption at that time, while continuing to assess supply-chain risk.
• The company relied on third parties, including single-source manufacturers, for drug substance and clinical supplies. Other principal risks included clinical and regulatory failure, dependence on collaborators, additional capital needs, competition, and intellectual-property protection.
• Management reported disclosure controls were ineffective at March 31, 2021 because material weaknesses remained in complex-transaction accounting expertise and period-end expense accrual and contractor-review controls. Remediation was underway but not yet validated as effective.
• No material legal proceedings were reported. The company disclosed related-party arrangements, including a lease with NovaPark, an entity affiliated with the Executive Chairman’s family.

Investor verification priorities

1. Confirm the issuer: the supplied filing is Angion Biomedica Corp., not Elicio Therapeutics, Inc.
2. Review subsequent clinical results and regulatory discussions regarding ANG-3777, particularly the FDA’s position on the delayed-graft-function trial endpoint.
3. Assess cash use against management’s stated runway, planned trial spending, and the need for future financing.
4. Examine the Vifor license’s deferred revenue, remaining milestones, royalty terms, obligations, and termination rights; milestone and royalty amounts are contingent, not assured.
5. Track remediation and testing of the disclosed internal-control material weaknesses.
6. Assess clinical supply concentration, COVID-related trial disruption, and the extent of reliance on collaborators and third parties.